Selected Publications

Parikh RB, Hubbard RA, Wang E, Royce TJ, Cohen AB, Clark AS, Mamtani R: Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval JAMA Oncol : doi: 10.1001/jamaoncol.2022.7770,2023.

Herrera CD, Guerra CE, Narayan V, Guzzo TJ, Mamtani R, Lee DJ, Tasian GE, Talwar R: Financial toxicity in prostate cancer survivors: A national cross-sectional assessment of subjective financial burden Urol Oncol : 2023.

Voruganti T, Soulos PR, Mamtani R, Presley CJ, Gross CP: Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy JAMA Oncol : 2023.

Roberson DS, Xia L, Lee DJ, Pierorazio PM, Malkowicz SB, Mamtani R, Guzzo TJ, Bivalacqua TJ.: Comparison of the 'iROC' trial participants to patients with bladder cancer in the United States undergoing radical cystectomy BJU Int : DOI: 10.1111/bju.15954,2022.

Shah M, Marmarelis ME, Mamtani R, Hennessy S.: Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer Clin Lung Cancer 23 (8): 2022.

Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA.: NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022 J Natl Compr Canc Netw 23 (8): 2022.

Gotschall JW, Major CK, Jacobs LA, Blauch A, Pucci D, Palmer SC, Mamtani R: Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot study BJUI Compass : doi: 10.1002/bco2.204,2022.

Herrera CD, Guerra CE, Narayan V, Guzzo TJ, Mamtani R, Lee DJ, Tasian GE, Talwar R: Financial toxicity in prostate cancer survivors: A national cross-sectional assessment of subjective financial burden Urol Oncol : doi: 10.1016/j.urolonc.2022.10.014,2022.

Bange EM, Coughlin K, Li W, Moriarty E, Brown TJ, Shulman LN, Mamtani R: Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint Inhibitors JAMA Netw Open 5 (8): 2022.

Nimgaonkar V, Hubbard RA, Carpenter EL, Mamtani R: Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy JAMA Oncol 8 (7): 2022.

Academic Contact Information

Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Phone: 215-662-7606
Patient appointments: 800-789-7366